125 related articles for article (PubMed ID: 2795995)
1. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
Okada K; Nagura Y; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. 1-alpha-OH-cholecalciferol (1-alpha-OHD3) and low phosphate diet in predialysis chronic renal failure: effects on renal function and on secondary hyperparathyroidism.
Coen G; Messa F; Massimetti C; Mazzaferro S; Manganiello M; Donato G; Finistauri D; Giuliano G; Cinotti GA
Acta Vitaminol Enzymol; 1984; 6(2):129-35. PubMed ID: 6496255
[TBL] [Abstract][Full Text] [Related]
4. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
[TBL] [Abstract][Full Text] [Related]
5. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
[TBL] [Abstract][Full Text] [Related]
6. Treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.
Okada K; Takahashi S; Nagura Y; Hatano M
Nihon Jinzo Gakkai Shi; 1989 Oct; 31(10):1085-9. PubMed ID: 2615019
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
[TBL] [Abstract][Full Text] [Related]
8. Calcium set point progressively worsens in hemodialysis patients despite conventional oral 1-alpha hydroxycholecalciferol supplementation.
Ali AA; Varghese Z; Moorhead JF; Baillod RA; Sweny P
Clin Nephrol; 1993 Apr; 39(4):205-9. PubMed ID: 8491050
[TBL] [Abstract][Full Text] [Related]
9. Administration of calcium carbonate with adequate doses of vitamin D metabolite to patients on hemodialysis improves mild secondary hyperparathyroidism.
Okada K; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1990 Aug; 32(8):899-903. PubMed ID: 2250406
[TBL] [Abstract][Full Text] [Related]
10. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
11. Role of CaCO3 alone and CaCO3 plus vitamin D3 in terms of calcium phosphorus product in chronic kidney diseases.
Adhikary L; Acharya S; Acharya L
J Nepal Health Res Counc; 2011 Apr; 9(1):67-70. PubMed ID: 22929717
[TBL] [Abstract][Full Text] [Related]
12. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
13. [Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].
Séchet A; Abighanem O; Said S; Rasombololona M; Morinière P; Brazier M; Fournier A
Nephrologie; 1999; 20(4):209-12. PubMed ID: 10480153
[TBL] [Abstract][Full Text] [Related]
14. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
Madsen S
Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
[No Abstract] [Full Text] [Related]
15. [Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia].
Djerad M; Morinière P; Westeel PF; el Esper N; Boitte F; Morsli R; Schenouda M; Compagnon M; Achard JM; Fournier A
Nephrologie; 1991; 12(4):193-7. PubMed ID: 1745337
[TBL] [Abstract][Full Text] [Related]
16. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
17. Calcium and parathyroid disorders in children. Chronic renal failure and treatment with calcitriol.
Chan JC; DeLuca HR
JAMA; 1979 Mar; 241(12):1242-4. PubMed ID: 762789
[TBL] [Abstract][Full Text] [Related]
18. Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure.
Alon U; Davidai G; Bentur L; Berant M; Better OS
Miner Electrolyte Metab; 1986; 12(5-6):320-5. PubMed ID: 3807830
[TBL] [Abstract][Full Text] [Related]
19. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
[TBL] [Abstract][Full Text] [Related]
20. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
